Hegazy SK, Tharwat S, Hassan AH. Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients. World J Clin Cases 2023; 11(26): 6105-6121 [PMID: 37731581 DOI: 10.12998/wjcc.v11.i26.6105]
Corresponding Author of This Article
Ahmed H. Hassan, BPharm, PharmD, Pharmacist, Researcher, Clinical Pharmacy, Mansoura University Hospital, No. 2 Street, El-gomhoria, Mansoura 35511, Egypt. ahmedony26@gmail.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Clinical Trials Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Samar Tharwat, Rheumatology and Immunology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura university, Mansoura 35511, Egypt
Ahmed Hosny Hassan, Clinical Pharmacy Department, Mansoura University Hospital, Mansoura 35511, Egypt
Author contributions: Hegazy SK designed research, and supervised research; Tharwat S supervised research; Hassan AH designed and performed research, wrote the paper, and analyzed data.
Institutional review board statement: The study was reviewed and approved by the Research ethics committee, ministry of health, Egypt, Faculty of Medicine, Mansour University, and the Research ethics committee, faculty of medicine, Tanta University.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ahmed H. Hassan, BPharm, PharmD, Pharmacist, Researcher, Clinical Pharmacy, Mansoura University Hospital, No. 2 Street, El-gomhoria, Mansoura 35511, Egypt. ahmedony26@gmail.com
Received: May 16, 2023 Peer-review started: May 16, 2023 First decision: July 18, 2023 Revised: July 18, 2023 Accepted: August 17, 2023 Article in press: August 17, 2023 Published online: September 16, 2023 Processing time: 114 Days and 21.2 Hours
ARTICLE HIGHLIGHTS
Research background
Various advances in immunotherapy against coronavirus disease 2019 (COVID-19) have emerged. Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Other antiviral therapy against COVID-19 includes remdesivir and favipiravir.
Research motivation
This study may change the protocol of treatment of COVID-19 patients.
Research objectives
The objectives are to compare the efficacy of antibodies cocktail (casirivimab and imdevimab), remdesivir, and favipravir in reducing the need for invasive mechanical ventilation.
Research methods
The study design is a single-blind non-randomized controlled trial Mansoura University Hospital owns the study’s drugs. The duration of the study was about 6 mo after ethical approval.
Research results
Casirivimab and imdevimab cause less need for O2 therapy, and invasive mechanical ventilation, also they achieve less duration of this need than remdesivir and favipiravir.
Research conclusions
Casirivimab and imdevimab achieve better clinical outcomes than remdesivir, and favipravir.
Research perspectives
COVID-19 catastrophe causes progress in research works to find an end to this crisis. With ending of 2021 year.
